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PENGESANAN DAN PENGENALPASTIAN ANTIGEN-EDARAN Toxoplasma 
gondii DAN PROTEIN KHUSUS PERUMAH DALAM TOXOPLASMOSIS 
MELALUI PENDEKATAN PROTEOMIK SERUM 
 
ABSTRAK 
Toxoplasma gondii merupakan parasit intrasel yang tersebar meluas di dunia. Jangkitan 
pada wanita hamil boleh mengakibatkan keguguran dan kecacatan janin dan boleh 
mengancam nyawa dalam perumah yang rentan daya tahan imun. Pelbagai kajian telah 
dilakukan untuk membangunkan asai pengesanan antigen T. gondii. Walaubagaimana-
pun, asai-asai ini tidak boleh didapati secara komersil, satu sebab kemungkinan 
kurangnya data yang baik berkaitan antigen-edaran Toxoplasma dalam darah pada 
individu terjangkit aktif. Kaedah proteomik sangat membantu dalam penemuan petanda 
jangkitan penyakit untuk tujuan diagnosa, dan pendekatan ini telah digunakan dalam 
kajian untuk mengenalpasti petanda jangkitan dalam serum yang berpotensi dalam 
toksoplasmosis. Pada awalnya, ELISA, menggunakan anti-Toxoplasma SAG1 (p30) 
monoklonal sebagai antibodi penangkap untuk mengesan antigen-edaran T. gondii di 
dalam sampel serum telah dibangunkan. Seterusnya, kajian profil protein bagi serum 
daripada jangkitan T. gondii telah dijalankan menggunakan elektroforesis 2-dimensi (2-
DE) diikuti dengan kajian identifikasi dan pencirian protein-edaran T. gondii dan protein 
khusus perumah di dalam sampel serum pesakit toksoplasmosis aktif menggunakan blot 
Western dan analisis spektrometri jisim. Menggunakan serum yang dicampurkan dengan 
protein larut Toxoplasma dan protein rekombinan SAG1, takat pengesanan ELISA 
xix 
 
masing-masing ialah 31.25 ng/ml and 62.50 ng/ml. Keputusan positif diperolehi 
sebanyak 28% (21/75) dan 11% (23/206) masing-masing bagi sampel serum 
toxoplasmosis aktif dan kronik. Analisis blot Western pada kumpulan sampel serum 
positif-antigen menunjukkan jalur antigenik dengan berat molekul 25 dan 75 kDa 
daripada sera pesakit dengan jangkitan aktif dan lima jalur antigenik dalam lingkungan 
saiz daripada 26 hingga 33 kDa daripada serum pesakit dengan jangkitan kronik. 
Selanjutnya untuk menganalisa dan mencirikan antigen-edaran T. gondii, elektroforesis 
2-dimensi digunakan untuk membandingkan profil protein serum bagi subjek terjangkit 
(n=31) dan normal (n=10). Daripada 21 sera jangkitan aktif, 29 kDa, 33 kDa dan 38 
kDa, masing-masing kelihatan dalam 19 (90.5%), 14 (66.7%) dan 11 (52.4%) gel 2-DE 
yang diwarnakan. Protein antigenik dikesan melalui pemblotan imuno menggunakan 
kumpulan sera dan IgM-HRP anti-manusia monoklonal. Tompok-tompok protein 
terpilih dicirikan menggunakan spektrometri jisim. Perbezaan yang ketara diperhatikan 
apabila sampel serum daripada pesakit terjangkit T. gondii dan kawalan normal 
dibandingkan, yang terdahulu menunjukkan peningkatan ekspresi yang signifikan bagi 
protein perumah α2-HS glycoprotein (AHS) and α1-B glycoprotein (ABG). Tiada 
perbezaan yang signifikan diperhatikan di dalam gel-gel pewarnaan perak  bagi protein 
khusus perumah daripada jangkitan aktif dan kronik, walaubagaimanapun yang 
terdahulu menunjukkan tindakbalas imun di dalam blot Western. Tambahan pula, tiga 
kelompok protein T. gondii dikesan di dalam sampel serum daripada jangkitan aktif, 
dinamakan (a) protein hipotetikal chrXII: 3984434-3 TGME49, (b) protein dual 
specificity phosphatase TGME49, catalytic domain TGME 49 dan (c) NADPH-
cytochrome p450 reductase TGME 49. Kajian ini telah mengenalpasti lima petanda 
xx 
 
jangkitan yang berpotensi dalam diagnosa toksoplasmosis, tiga adalah protein khusus-
parasit dan dua adalah protein khusus-perumah.  
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DETECTION AND IDENTIFICATION OF CIRCULATING Toxoplasma gondii 
ANTIGENS AND HOST SPECIFIC PROTEINS IN TOXOPLASMOSIS VIA 
SERUM PROTEOMIC APPROACH 
 
ABSTRACT 
Toxoplasma gondii is an intracellular parasite of world-wide distribution. Infection 
in pregnant women may result in abortion and foetal abnormalities, and may be life-
threatening in immunocompromised hosts. Many studies have been performed on 
developing an antigen detection assay for T. gondii. However, such assay is 
unavailable commercially, one reason may be due to lack of good data regarding 
Toxoplasma circulating antigens in the blood of actively infected individuals. 
Proteomics has greatly aided in discovery of disease infection markers for diagnostic 
purposes, thus this approach was used in this study to identify potential serum 
infection markers in toxoplasmosis. Initially, an ELISA employing monoclonal anti-
Toxoplasma SAG1 (p30) as the capture antibody to detect T. gondii circulating 
antigens in serum samples was developed. Subsequently a study on protein profiles 
of serum from Toxoplasma gondii infection using two dimensional electrophoresis 
(2-DE) was performed, followed by identification and characterization studies of the 
circulating T. gondii proteins and host specific proteins in the serum samples of 
active toxoplasmosis patients by Western blot and mass-spectrometry analysis. 
Using serum spiked with Toxoplasma soluble and with SAG1 recombinant proteins, 
the ELISA detection limits were found to be 31.25 ng/ml and 62.50 ng/ml 
xxii 
 
respectively. Positive results were obtained in 28% (21/75) and 11% (23/206) of 
serum samples from active and chronic toxoplasmosis respectively. Western blot 
analysis on pooled antigen-positive serum samples showed antigenic bands of 
molecular weights 25 and 75 kDa from sera of patients with active infection and five 
antigenic bands ranging in size from 26 to 33 kDa from sera of patients with chronic 
infection. To further analyse and characterize the circulating T. gondii antigens, a 
two dimensional electrophoresis was used to compare serum protein profiles of 
infected (n=31) and normal (n=10) subjects. Antigenic proteins were identified by 
immunoblotting using pooled sera and monoclonal anti-human IgM-HRP. Out of the 
21 sera from active infection, 29 kDa, 33 kDa and 38 kDa  were seen in 19 (90.5%), 
14 (66.7%) and 11 (52.4%) respectively of  the stained 2-DE gels. Selected protein 
spots were characterized using mass spectrometry. Prominent differences were 
observed when serum samples from T. gondii infected patients and normal controls 
were compared, the former showed significant up-regulation of host proteins α2-HS 
glycoprotein (AHS) and α1-B glycoprotein (ABG). No significant difference was 
observed in the silver-stained gels of host-specific proteins from active and chronic 
infections, however only the former showed immunoreactivity in Western blots. In 
addition, three clusters of T. gondii proteins were detected in serum samples from 
active infection, namely (a) hypothetical protein chrXII: 3984434-3 TGME49, (b) 
dual specificity protein phosphatase TGME49, catalytic domain TGME 49 and (c) 
NADPH-cytochrome p450 reductase TGME 49. The study has identified five 
potential infection markers for diagnosis of toxoplasmosis, three are parasite-specific 
proteins and two are host-specific proteins. 
1 
 
CHAPTER ONE 
 
 
INTRODUCTION 
 
1.1 General Introduction on Toxoplasmosis 
 
Toxoplasmosis is a worldwide disease caused by Toxoplasma gondii, an intracellular 
protozoan parasite in the order Coccidia (phylum Apicomplexa). It was documented that 
over half a billion of the human population have serum antibodies to T. gondii (Dubey, 
1997b). In recent years, the importance of toxoplasmosis has been increasingly 
recognized. The course of infection by T. gondii is generally benign, as the vast majority 
of the infected individual remains asymptomatic or presents only with mild symptoms. 
However, the infection can cause significant morbidity and mortality in the developing 
foetus and in immunocompromised individuals.  
 
Infection during pregnancy in serologically negative women can lead to parasite 
transmission to the foetus via placenta, and thus can give rise to congenital 
toxoplasmosis (CT) of the newborn to a severe extent (Remington et al., 1995). 
Immunocompromised persons, such as those with acquired immune deficiency 
syndrome (AIDS), some organ transplant recipients and cancer patients receiving 
immunosuppressive therapy may suffer recrudescent active toxoplasmosis (Bretagne, 
1995; Maschke et al., 1999). Therefore, by understanding the nature of T. gondii and 
overall aspect of toxoplasmosis may lead to a better prevention, diagnosis and treatment 
of the disease. 
 
2 
 
1.2 History of the Discovery of Toxoplasma gondii  
T. gondii was first described in 1908 by Nicolle and Manceaux (Nicolle and Manceaux, 
1909) in a rodent Ctenodactylus gundi, and by Splendore in a rabbit. Based on the 
morphology, the name Toxoplasma was derived from a Greek word “toxo” meaning arc 
or bow, referring to the curved shape of the trophozoite (Figure 1.1) and “plasma” 
referring to life (Nicolle & Manceaux, 1909). The pathogenicity of the protozoan, T. 
gondii to human infants was pointed out by Wolf et al., (1939) who isolated the 
organism from children who had died from congenital encephalomyelitis. The discovery 
of Sabin-Feldman dye test as the first serological assay for Toxoplasma antibody in 1948 
(Sabin and Feldman, 1948), opened wide the scope and extent of the study on this 
infection. 
 
1.3 Epidemiology of Human Toxoplasmosis 
T. gondii infection is widespread in human and prevalence varies substantially according 
to countries. It is estimated that more than 60 million people in the United States are 
infected with T. gondii (CDC, 2007) and that approximately one-third of the world’s 
population has been exposed to the parasite (Tenter et al., 2000). In the United 
Kingdom, it was reported that 16-40% of people are infected whereas in continental 
Europe, the infection estimates reached up to 50-80% (Dubey and Beattie, 1988; Jones 
et al., 2001b; Tenter et al., 2000). The Centre for Disease Control (CDC) in the USA 
estimates that anywhere from 400 to 4,000 cases of congenital toxoplasmosis occur each 
year (CDC, 2007). The incidence of prenatal infection with T. gondii is estimated to be 
anywhere from 1-120 in every 10,000 births. In the early stages of pregnancy, about  
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   Figure 1.1. Toxoplasma gondii tachyzoites, stained with Giemsa, from a 
  smear of peritoneal fluid obtained from a laboratory-inoculated mouse. 
  Reference:
  
www.dpd.cdc.gov/DPDx/HTML/ImageLibrary/SZ/ 
 
Toxoplasmosis/ 
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10% of the fetal infection with T. gondii results in abortion or neonatal death. Another 
10-23% of infected infants show signs at birth like encephalomyelitis, retinochoroiditis, 
convulsions, hydrocephalus, splenomegaly, hepatomegaly, fever, anaemia, jaundice or 
lymphadenopathy. About 12 to 16% of infants born die from the disease, and survivors 
suffer from progressive neural disorders such as mental retardation or seizures (Tenter et 
al., 2000). In immunocompromised individuals, such as those with HIV/AIDS, organ 
transplant and chemotherapy patients, toxoplasmosis is an opportunistic infection that 
poses a significant risk. Latent infection can be reactivated to cause encephalitis, which 
can be fatal (Singh et al., 2005). Severe encephalitis occurs in up to 40% of AIDS 
patients and it is estimated that 10-30% of AIDS patients worldwide are infected with T. 
gondii (Tenter et al., 2000).  
 
In Malaysia, anti-Toxoplasma antibodies have been shown to be present in the local 
population (Osman et al., 1992), as well as among the pregnant women and women of 
child-bearing age. The seroprevalence of toxoplasmosis in pregnant women was found 
to be 49%, in which 39%, 4% and 6% were positive for anti-Toxoplasma IgG, IgM and 
both anti-Toxoplasma IgG and IgM antibodies, respectively (Azmi et al., 2003). It was 
also reported that there was a significant difference (p<0.05) in rates of Toxoplasma 
seroprevalence among races; the highest rate was in the Malays (55.7%), followed by 
the Indian (55.3%) and the Chinese (19.4%) (Azmi et al. 2003). The relatively higher 
rate of Toxoplasma infection in Malays may be attributed to their close association with 
cats as compared to the other races. In spite of the fact that pigs have the highest 
infection rate among domestic animals, the Chinese population who consume pork more 
than any other meat had the lowest infection rate (Tan and Mak, 1985). This could be 
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due to the fact that the Chinese in Malaysia usually cook their meat thoroughly before 
eating, thus avoiding infection. 
 
A finding reported by Osman et al. (1992) revealed that in congenital toxoplasmosis 
(IgM positive), only 12 (0.35%) of 3420 infants were clinically suspected of acquiring 
congenital infection. The main clinical features of congenital abnormalities in Malaysia 
are hepatomegaly, neonatal jaundice, hydrocephalus, microcephalus, ocular lesion and 
general illness (Osman et al., 1992; Tan and Mak., 1985). A study conducted in 2003 by 
(Nissapatorn et al., 2003) reported that the seroprevalence of toxoplasmosis among 406 
AIDS patients in Kuala Lumpur Hospital was 208 (51.2%). This seroprevalence was 
much higher than in other similar studies e.g. 15-37% in France (Leport and Remington, 
1992), 21% in Malaysia (Nissapatorn et al., 2002), 22.4% in Thailand (Nissapatorn et 
al., 2001) and 10-40% in USA (Luft and Remington, 1988). The majority of the patients 
were males (82.6%), Malays (47.5%), single (52.4%), unemployed (47.6%) and 
heterosexuals who engaged commercial sex workers (46.6%) and were at risk to HIV 
infection. 
 
The socioeconomic impact of toxoplasmosis in terms of human suffering and long term 
care of children with mental retardation and blindness are enormous (Roberts et al., 
1994). Testing of all pregnant women for T. gondii infection is compulsory in France 
and Austria, and the cost benefits of such mass screening are being debated in many 
countries (Remington et al., 2001). For immunocompromised patients due to 
HIV/AIDS, the risk of toxoplasmosis however has decreased after introduction of 
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primary prophylaxis against T. gondii and effective antiretroviral therapy (ART) (Jones 
et al., 1999). 
 
1.4 Life Cycle of Toxoplasma gondii 
T. gondii is a coccidian parasite and capable of infecting a wide range of hosts and many 
different host cells (Dubey and Beattie, 1988; Dubey et al., 1998a). Generally, coccidia 
have a complex life cycle. In order to understand the transmission of T. gondii and how 
it infects the body, it is important to understand its life cycle. The life cycle of T. gondii 
is facultatively heteroxenous (Figure 1.2). All warm-blooded animals including most 
livestocks and humans serve as its intermediate hosts. Definitive hosts are members of 
the family Felidae, for example domestic or stray cats, including wild Felidae such as 
lions and tigers (Dubey and Beattie, 1988; Dubey et al., 1998b; Frenkel, 2000; Jackson 
and Hutchison, 1989; Levine, 1961). One study revealed that only felids were found to 
shed T. gondii oocysts (Frenkel et al., 1970; Miller et al., 1972). Results of epidemiolog- 
ic studies indicated that most cats in the wild become infected soon after they are 
weaned by eating infective animal tissues. During controlled studies, most uninfected 
cats that are fed tissues containing bradyzoites will shed oocysts, whereas less than half 
of the cats that are fed oocysts will shed oocysts (Dubey and Frenkel, 1972). Moreover, 
the number of oocysts shed by a cat after ingestion of oocysts is far fewer than after 
ingestion of bradyzoites in infective tissues. The ingestion of infected rodents and birds 
by cats can lead to excretion of large numbers of environmentally resistant oocysts. 
Transplacental infection can develop in cats, and kittens infected in utero can shed T. 
gondii oocysts after birth (Dubey et al., 1993; Sato et al., 1993). Although cats can shed 
T. gondii oocysts after reinfection (or even without reinfection),  
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               Figure 1.2. Life cycle of T. gondii  
    Reference: (Aliberti, 2005) 
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shedding of oocysts in in cats in the wild is unknown (Dubey and Frenkel, 1974). 
 
In intermediate hosts, T. gondii undergoes two phases of asexual development. In the 
first phase, tachyzoites multiply rapidly by repeated endodyogeny in many different 
types of host cells. Tachyzoites of the last generation initiate the second phase of 
development which results in the formation of tissue cysts. Within the tissue cysts, 
bradyzoites multiply slowly by endodyogeny (Dubey, 1986; Dubey, 1993; Dubey and 
Beattie, 1988; Frenkel, 2000; Levine, 1961). These cysts are most often located within 
the eye, central nervous system and skeletal or cardiac muscles. To a lesser extent, it 
may occur in the liver, kidney and lungs (Dubey, 1993; Dubey, 1998b; Dubey et al., 
1998; Levine, 1961). In some intermediate host species, bradyzoites may persist for life 
in the host. However, it is still unknown how the persistence mechanism occurs. Many 
investigators believed that tissue cysts break down periodically, with bradyzoites 
transforming to tachyzoites that reinvade host cells and again transform to bradyzoites 
within new tissue cysts (Dubey, 1998a; Dubey, 1998b; Dubey et al., 1998; Evans, 1992; 
Frenkel, 2000; Levine, 1961; Remington and Desmonts, 1990; Weiss et al., 1988). If 
ingested by definitive hosts, the bradyzoites initiate another asexual phase of 
proliferation which consists of initial multiplication by endodyogeny followed by 
repeated endopolygeny in epithelial cells of the small intestine. The terminal stages of 
this asexual multiplication initiate the sexual phase of the life cycle.  
 
Sporogony and oocyst formation take place in the epithelium of the small intestine of 
felines. Unsporulated oocysts are released into the intestinal lumen and passed into the 
environment with the faeces. Sporogony occurs outside the host and leads to the 
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development of infectious oocysts which contain two sporocysts, each containing four 
sporozoites (Dubey, 1993; Dubey and Beattie, 1988; Dubey et al., 1998; Evans, 1992; 
Jackson and Hutchison, 1989; Levine, 1961). Oocysts can spread in the environment and 
contaminate water, soil, fruits, vegetables and herbivores are infected following 
consumption of contaminated plants material. Oocysts have been found to be very 
stable, especially in warm and humid environments, and resistant to many disinfecting 
agents (Dumetre and Darde, 2003), but survive poorly in arid, cold climates (Jones et al., 
2001a). 
 
1.5 Transmission of Human Toxoplasmosis 
Transmission of T. gondii in human beings can occur by several routes. The routes of 
infection rely on the infectious stages of the parasite. There are three infectious stages of 
T. gondii for all hosts: tachyzoites, bradyzoites (in tissue cysts) and sporozoites (in 
oocysts). Figure 1.3 shows the images of bradyzoites and oocyst of T. gondii. All three 
stages are infectious for both intermediate and definitive hosts. In most cases, infection 
with T. gondii occur inadvertently, thus the specific route of transmission cannot usually 
be established. A person may acquire a T. gondii infection mainly via one of the 
following routes; horizontally by oral ingestion of infectious oocysts from the 
environment, horizontally by oral ingestion of tissue cysts contained in raw or 
undercooked meat or vertically by transplacental transmission of tachyzoites (Dubey, 
1991; Dubey, 1993; Dubey and Beattie, 1988; Dubey et al., 1998; Evans, 1992; Jackson 
and Hutchison, 1989; Remington and Desmonts, 1990).  
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                    Figure 1.3. Images of tissue cyst and oocyst of T. gondii 
 
 
 
 
 
a) The tissue cyst of T. gondii contains bradyzoites surrounded by the cyst wall.       
    (Reference: www.parasite.org.au) 
 
  
b) T. gondii sporulated oocyst in an unstained wet mount 
   (Reference: http://www.dpd.cdc.gov) 
 
Tissue cyst wall 
Bradyzoites 
Oocyst wall 
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1.5.1 Faecal-Oral Route 
Seroprevalence reports of human toxoplasmosis indicated a correlation with eating and 
hygiene habits of a population. This finding lends support to the contention that the 
faecal oral route is the major source of infection (Cook et al., 2000; Desmonts et al., 
1965; Remington et al., 2001). A study in Bombay, India found that the prevalence of T. 
gondii in strict vegetarians to be similar to that in non-vegetarian (Rawal, 1959). 
However, a later study by Roghmann et al. (1999) has proved that avoidance of meat in 
daily diet resulted in significant reduction in risk of infection to toxoplasmosis. The 
widespread infection of toxoplasmosis in vegetarian is explained by this route of 
transmission.  
 
Epidemics of human toxoplasmosis attributed to exposure to infected cats indicate an 
important role of oocyst excretion by cats in the propagation of infection in nature and 
man (Teutsch et al., 1979). Infected cat sheds large numbers of oocysts which are able to 
survive for months in moist soil (Frenkel et al., 1970) and becomes a source of infection 
to a variety of animals and man. Chronically infected cats have been shown to reshed T. 
gondii oocysts in the absence of reinfection (Dubey, 1976) increasing the chances of 
environmental contamination of oocysts. Several outbreaks of toxoplasmosis in human 
beings also have been linked to drinking of unfiltered water (Bahia-Oliveira et al., 2003; 
Bowie et al., 1997).  Toxoplasmosis may be equally important in many other developing 
countries, where the lack of adequate sanitary conditions expose populations to a variety 
of diseases. Contamination of household items with oocysts from soil is likely to occur 
in floods or runoffs that are frequent after rainfall. Since oocysts can survive for long 
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periods in water (Dubey, 1988), the lower socioeconomic population may frequently be 
exposed to T. gondii oocysts from drinking water (e.g. river and well). 
 
1.5.2 Carnivorism 
Transmission of T. gondii through carnivorism was first suggested by Weinman and 
Chandler, (1954). The idea was supported by demonstrating the resistance to proteolytic 
enzymes of T. gondii derived from cysts (Jacobs et al., 1960a). They found that the cyst 
wall was immediately dissolved by such enzymes but the released bradyzoites survived 
long enough to infect the host. Ingestion of viable cysts present in meat may result in 
infection, particularly among people who habitually eat raw or undercooked meat. T. 
gondii is killed when the internal temperature of the meat reaches 66oC (Dubey, 1988). 
T. gondii however may survive in improperly grilled or barbecued meat. Durfee (1976) 
reported that in South Kalimantan (Indonesia), goat meat acts as a source of infection to 
man due to eating undercooked goat ‘sate’.  
 
1.5.3 Congenital Transmission 
Congenital transmission of toxoplasmosis can occur transplacentally during primary 
infection of a pregnant woman. The mechanism of this vertical transmission is not yet 
understood. A probable scenario is that temporary parasitaemia in a primary infected 
pregnant women may result in invasion of the placenta by tachyzoites which then 
multiply within cells and placenta. Eventually, some of these may cross the placenta and 
enter the fetal circulation or fetal tissues (Ebbesen, 2000; Remington and Desmonts, 
1990).  For a primary Toxoplasma infection, the mother has no antibodies against T. 
gondii, thus the organisms (tachyzoites) are able to cross the placental barrier into the 
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foetus. However, if the mother was infected previously, the organisms are destroyed 
before it can cross the placenta. The foetus of a previously infected mother is therefore 
protected. 
 
Early maternal infection (first and second trimester) may result in severe congenital 
toxoplasmosis and can result in death of the foetus in utero and spontaneous abortion. 
By contrast, late maternal infection (third trimester) usually results in normal appearing 
newborns (Montoya and Liesenfeld, 2004). Infection initially goes unnoticed, but if it is 
not treated, babies can develop chorioretinitis or physical growth can be delayed in the 
second or third decade of life (Remington et al., 2001; Wilson et al., 1980). Vertical 
transmission of T. gondii in the setting of chronic infection is only recorded in 
immunocompromised women- i.e, those with AIDS or receiving immunosuppressive 
drugs. However, the rate of vertical transmission in this setting seems to be fairly low 
(Minkoff et al., 1997).  
 
1.5.4 Organ Transplantation and Blood Transfusion 
In recent years, it has been found that organ transplantation of heart, kidney, liver and 
bone marrow from a seropositive donor to a seronegative recipient may be complicated 
by T. gondii infections. In these cases either tachyzoites or tissue cysts may be involved 
(Dubey and Beattie, 1988; Ho Yen, 1992). Reactivation of latent infection in the 
recipient is the most usual mechanism for toxoplasmosis to arise in bone marrow, 
haematopoietic stem cell and liver transplant patients and in people with AIDS.  
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Although rare, T. gondii can also be transmitted via blood or leukocytes from 
immunocompetent and immunocompromised donors (Raisanen, 1978; Siegel et al., 
1971). However, parasitaemia usually occurs for only a short period of time after 
primary infection. Therefore it has been suggested that there is only a low risk of 
acquiring an infection with T. gondii via ordinary blood transfusion (Dubey and Beattie, 
1988). 
 
1.5.5 Other Routes of Transmission 
 
Toxoplasma is also known to be able to enter the body by several other ways, for 
instance through conjunctiva, respiratory and cutaneous routes (Beverly, 1973). 
Accidental laboratory infections have been reported and arisen from various laboratories 
by contact with contaminated needles and glassware or infected animals (Kayhoe et al., 
1957; Remington and Gentry, 1970). There was also a report of toxoplasmosis in a 
breast-fed infant whose mother acquired primary infection with T. gondii (Bonametti et 
al., 1997).  
 
1.6 Clinical Manifestations, Pathogenesis, Treatment and Prevention of 
 Toxoplasmosis 
Toxoplasmosis is a systemic disease. Clinically, infection with T. gondii can go 
unnoticed or could cause signs and symptoms depending on the immune status of the 
patient and the clinical settings - eg, immunocompetent, congenital toxoplasmosis, 
immunocompromised or ocular disease. 
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1.6.1 Immunocompetent Adults and Children 
 
Primary infection of T. gondii in children and adults (including pregnant women) is 
asymptomatic in most patients since particularly large numbers of the population with T. 
gondii antibody do not recall an illness with relevant symptoms (Frenkel, 1973). It 
causes a self-limited and non-specific illness and rarely needs treatment. General 
symptoms of toxoplasmosis in immunocompetent individuals are fever, lymphadeno-
pathy, headache, sore throat, cough, myalgia, and dizziness. However, when patients 
with lymphadenopathy were studied, non-specific gastrointestinal symptoms such as 
nausea, vomiting, and abdominal pain were prominent (Tenhunen, 1964). Very 
infrequently, myocarditis, polymyositis, pneumonitis, hepatitis or encephalitis can arise 
in healthy individuals. (Montoya and Liesenfeld, 2004). 
 
1.6.2 Congenital Toxoplasmosis 
 
Congenital T. gondii infection in a human was initially described by Wolf et al., (1939). 
Infection acquired during pregnancy may cause severe damage to the foetus, which can 
lead to a wide array of manifestations, ranging from mild chorioretinitis which can 
present many years after birth, to miscarriage, mental retardation, microcephaly, 
hydrocephalus and seizures. In congenital toxoplasmosis cases, data on clinical 
manifestations in both maternal and foetal infection are important to aid diagnosis of the 
disease. 
 
 
1.6.3 Maternal Infection  
Congenital infection may occur following maternal infection during pregnancy. Every 
instance of primary maternal toxoplasmosis occurring during pregnancy exposes the 
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foetus to the risk of infection via the transplacental route, whereas the foetus is protected 
when maternal infection occurs prior to pregnancy. The severity of the disease may 
depend upon the stage of pregnancy at the time of infection. The likelihood of clinical 
symptoms in the newborn is reduced when infection occurs later in the pregnancy. 
Infection acquired during the first trimester by women not treated with anti T. gondii 
drugs results in congenital infection in 10 to 25% of cases. For infection occurring 
during the second and third trimesters, the incidence of foetal infection ranges between 
30-54% and 60-65%, respectively (Lynfield and Guerina, 1997). The consequences are 
more severe when fetal infection occurs in early stages in pregnancy, when it can cause 
miscarriage (Remington and Desmonts, 1990), severe disease, intra-uterine growth 
retardation or premature birth. The highest frequency of severe abnormalities at birth is 
seen in children whose mothers acquired a primary infection between 10th and 24th week 
of gestation (Remington and Desmonts, 1990). 
 
Primary infection acquired during pregnancy is asymptomatic in about 60% of cases 
(Daffos et al., 1988). Like in immunocompetent adult, infected pregnant women are 
asymptomatic or have only mild and non-specific symptoms such as fatigue, malaise, 
low grade fever, myalgia and lymphadenopathy. Although signs of active infections are 
commonly unrecognized and not noticed by patients, however, when the serology of 
pregnant woman suggests a recent infection, it is important to search for symptoms by 
retrospective questioning, since the time of their onset may reliably indicate the time of 
infection with respect to the date of conception (Thulliez, 2001). Since the clinical 
features of maternal infection are not diagnostic, identification of primary infections 
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occurring in a given population of pregnant women requires systematic serological 
screening.  
 
1.6.4 Foetal Infection 
The risk of fetal infection is multifactorial, depending on the time of maternal infection, 
immunological competence of the mother during parasitaemia, parasite load and strain 
virulence (Tenter et al., 2000). Infection of the placenta is a prerequisite for congenital 
transmission as the placenta acts as a source of parasites which are transmitted to the 
foetus almost immediately after maternal infection but possibly with a delay of several 
weeks or longer (Remington et al., 1995). A wide spectrum of clinical disease occurs in 
congenitally infected children (Jones et al., 2001a; Remington et al., 2001). Mild disease 
may consist of slightly diminished vision only whereas severely diseased children may 
have the full tetrad of signs including retinochoroiditis, hydrocephalus, convulsions and 
intracerebral calcification. Of these, hydrocephalus is the least common but most 
dramatic lesion of congenital toxoplasmosis (Dubey, 2004).  
 
Foetuses with congenital toxoplasmosis usually look normal in prenatal ultrasound. If 
present, ultrasonographic findings suggestive of congenital disease include intracranial 
calcifications, ventricular dilatation, hepatic enlargement, ascites and increased placental 
thickness (Gay-Andrieu et al., 2003). Neonatal clinical manifestations of congenital 
toxoplasmosis vary widely and include hydrocephalus, microcephaly, intracranial 
calcifications, chorioretinitis, strabismus, blindness to thrombocytopenia and anaemia 
(McAuley et al., 1994; Swisher et al., 1994). The classic triad of chorioretinitis, 
hydrocephalus and cerebral calcification is rather rare. None of the signs described in 
18 
 
newborns with congenital disease is pathognomonic for toxoplasmosis and can be 
mimicked by congenital infection with other pathogens, including cytomegalovirus, 
herpes simplex virus, rubella and syphilis (Montoya and Liesenfeld, 2004).   
   
1.6.5 Immunocompromised Patients  
 
By contrast with the favourable course of toxoplasmosis in almost all immunocompetent 
individuals, toxoplasmosis can be life-threatening in those who are immunocomprom-
ised (Liesenfeld et al., 1999). In patients infected with AIDS, the overwhelming 
majority (>95%) of toxoplasmosis cases occur as a consequence of reactivation of a 
dormant (latent) infection (Luft and Remington, 1992). Encephalitis is the clinically 
important manifestation of toxoplasmosis in AIDS patients and in fact, the most 
common cause of death among toxoplasmosis patients with AIDS (Dubey, 2004). 
 
The clinical manifestations of toxoplasmic encephalitis depend upon the location, 
number and size of the lesions. Toxoplasmic encephalitis may present with focal or 
generalized signs and symptoms of central nervous system dysfunction (Levy et al., 
1985; Luft and Remington, 1992; McArthur, 1987; Navia et al., 1986). Clinical 
presentation of toxoplasmic encephalitis varies from a subactive gradual process 
evolving over weeks to an active confusional state, with or without focal neurological 
deficit, evolving over days. Clinical manifestations include mental status changes, 
seizures, focal motor deficits, cranial nerve disturbances, sensory abnormalities, 
cerebellar signs, movement disorders and neuropsychiatric findings. Meningeal signs are 
rare. Constitutional symptoms and signs such as fever and malaise can vary. The most 
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typical focal neurological findings are hemiparesis and speech abnormalities (Luft et al., 
1993). 
 
1.6.6 Ocular Toxoplasmosis  
Toxoplasmic chorioretinitis can be seen in the setting of congenital or postnatally 
acquired disease as a result of active infection or reactivation (Holland, 1999; Montoya 
and Remington, 1996). Focal retinochoroiditis is the most frequent outcome of infection 
of the eye by T. gondii. Retinochoroiditis in individuals with active acquired 
toxoplasmosis can arise sporadically or in the context of an outbreak of active disease 
(Burnett et al., 1998). The natural history of the disease is for an active inflammatory 
lesion of retina to slowly resolve, leaving a focus of retinochoroidal scarring (Koch et 
al., 1943). Recurrent lesions are usually recorded at the borders of chorioretinal scars, 
which are typically found in clusters. Patients suffering from active toxoplasmic 
retinochoroiditis characteristically present with symptoms of unilateral, mild ocular pain, 
blurred vision and new onset of floating spots which may be associated with discomfort 
(Dutton, 2001). Further clinical signs which may develop include segmental periarteritis 
(O'Connor, 1970), retinal and vitreous haemorrhage (Rieger, 1952), choroidal or retinal 
neovascularization (Fine et al., 1981; Gaynon et al., 1984; Malbrel, 1981), branch artery 
occlusion (Braunstein and Gass, 1980; Willerson et al., 1977) and retinochoroidal 
anastomoses (Kennedy and Wise, 1971; Owens et al., 1979).    
 
Retinochoroiditis in adults has been traditionally deemed a late manifestation and 
reactivation of congenital disease; however, it has been reported with increasing 
frequency in association with active infection (Montoya and Remington, 1996). It is 
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difficult to establish whether the original infection was congenital or acquired in patients 
who have recurrences of chorioretinitis. 
 
1.6.7 Toxoplasmosis and Brain Diseases 
Schizophrenia and related psychotic illness are a class of pervasive neuropsychiatric 
disorders of uncertain origin (Buka et al., 2001). Early exposure to several infectious 
agents has been associated with the later development of schizophrenia (Mortensen et 
al., 2007). Epidemiological studies have also found that infections known to cause 
congenital central nervous system abnormalities in humans, including rubella, herpes 
simplex, polio and varicella zoster virus, might be related to the risk of schizophrenia 
(Amminger et al., 2007; Flegr et al., 2003). Schizophrenia is also associated with 
maldevelopment of the central nervous system and ecological data has led to the 
suggestion that T. gondii might be involved in its aetiology (Brown et al., 2005). 
 
 
One study has found that patients with psychosis had significantly elevated levels of IgG 
antibodies to T. gondii compared with control (Tamer and Dundar, 2008). The finding is 
in accordance with a previous research which has shown an increase in the antibody 
response to Toxoplasma proteins in schizophrenia (Yolken et al., 2001). This suggests 
that T. gondii could play a role in the aetiology of schizophrenia. Interestingly, anti- T. 
gondii IgM antibody, a key indicator of active acquired infection, is not elevated in the 
sera of patients with first-onset schizophrenia (Torrey et al., 2006; Wang et al., 2006) 
implying that the patients are not in the active stage of a newly acquired infection. 
Therefore, a reactivation of chronic infection with the parasite (proliferation of 
tachyzoites caused by cyst rupture) in the brain might be involved in the onset of the 
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disease. In support of this possibility, it is noteworthy that individuals with congenital T. 
gondii infection often develop ocular toxoplasmosis later in life (Remington et al., 2001) 
and the disease is considered to be due to reactivation of infection. These results are 
consistent with studies indicating that T. gondii infection of the brain can result in 
behavioral alterations in experimentally infected animals (Holliman, 1997). A very 
interesting study by Webster et al., (2006) has demonstrated that several commonly used 
medications of antipsychotics such as Fluphenazine HCl, Chlorpromazine and 
Clozapine, for treating schizophrenia have the ability to inhibit the replication of T. 
gondii.  
 
The onset of toxoplasmic chorioretinitis is most frequent during the ages of 20–30 years 
(Remington et al., 2001) correlating well with the age of onset of schizophrenia (Hafner 
et al., 1993). Therefore, congenital infection with T. gondii may be involved in the 
aetiology of schizophrenia. Another brain disease, epilepsy has also been associated with 
T. gondii. In Turkey, Yazar et al., (2003) reported that in a study of cryptogenic epilepsy 
cases and healthy individuals the level of T. gondii IgG showed a statistically 
significantly high value in epileptic patients. However, a contradicted finding by Akyol 
et al., (2007) reported that there wasn’t any relationship between epilepsy and positive 
T. gondii serology in epileptic patients. All of the above reports had revealed recent 
discoveries of association between toxoplasmosis and brain diseases which warrant 
further study for confirmation. 
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1.7 Laboratory Diagnosis of Toxoplasmosis 
The diagnosis of toxoplasmosis may be established by various methods including 
serological tests, polymerase chain reaction (PCR) and histological demonstration of the 
organism or isolation of the organism. For instance, the Toxoplasma Serology 
Laboratory of the Palo Alto Medical Foundation Research Institute, United States (TSL-
PAMFRI) offers a panel of tests, the Toxoplasma Serological Profile (TSP) which 
comprised of the Sabin-Feldman Dye Test (SFDT), double sandwich IgM ELISA, IgA 
ELISA, IgE ELISA and AC/HC test (http://www.pamf.org/serology). The 
discriminatory power of the TSP has been clinically helpful to differentiate between 
recent and chronic infections to any single serological test.  
 
1.7.1 Sabin Feldman Dye Test (SFDT) 
SFDT is the first test developed for the laboratory diagnosis of T. gondii infection (Sabin 
and Feldman, 1948) and it is still considered as the “gold standard”. The principle of this 
assay is based on binding of specific T. gondii antibodies to the surface of viable 
trophozoites and fixes complement with resultant damage to the parasite cell wall. When 
this reaction occurs the organism is not capable of retaining a vital stain, alkaline 
methylene blue. Performance of dye test requires a source of live, Toxoplasma and 
detects the presence of anti- T. gondii specific antibodies. This is the reason why this 
assay is usually performed in reference centres. SFDT in infected pregnant woman is 
performed by taking consecutive serum samples at least 3 weeks apart to determine the 
change in antibody titer for the evaluation of the infection. A “significant” change is 
considered to be at least a four-fold difference in titre. The absolute antibody titer is also 
important whereby values over 250 IU/ml are considered “high” and suggestive of 
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recent infection (Rorman et al., 2006). SFDT is able to determine early arising IgG 
antibody as its reactivity appears within 1 to 2 weeks of infection. IgG antibody usually 
appear within 1 to 2 weeks of the infection, peaks within 1 to 2 months, decline 
gradually over many months or years and usually low titres commonly persist for life 
(Holliman, 1990). 
 
The tested sera is serially diluted and incubated with live tachyzoites (carrying 
Toxoplasma antigens) in the presence of separated human plasma from “sero-negative” 
donors (providing complement components). If the patient’s serum contains antibodies 
to Toxoplasma, formation of the antigen-antibody-complement complexes subsequently 
lysed the tachyzoites in the presence of the dye methylene blue. End point titer is 
determined by counting the number of dead (unstained) and live (stained) parasites. End 
point titer can be converted to international units (IU): additional standardization is 
achieved by preparation of a standardised control serum (consisting of a pool of sera), 
tested by numerous reference centres, and adjusted so that the SFDT value of this 
control serum is set at 1000IU/ml (Reiter-Owona et al., 1999).  
 
1.7.2 Indirect Fluorescent Assay (IFA) 
The IFA is widely used to demonstrate T. gondii –specific antibodies.  Serially diluted 
serum samples are incubated with live, inactivated Toxoplasma fixed to a glass slide. 
Binding of specific T. gondii antibodies present in the serum to the inactivated parasite 
occurs and the complex is then detected using fluorescein isothiocyanate-labeled anti-
human immunoglobulin (or anti-IgG or anti-IgM). IFA is safer to perform and more 
economical than SFDT. It appears to measure the same antibodies as the dye test, and its 
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titres tend to parallel dye test titres (Araujo et al., 1980; Dubey and Beattie, 1988). 
However, the interpretation of this assay involves subjective assessment of the degree of 
fluorescent present and is time consuming.  
 
False positive reactions were reported to associate with polar staining in sera containing 
antinuclear antibodies and rheumatoid factor (Wilson et al., 2003). Moreover, some false 
positive reactions due to polar staining have been found to involve the expression of Fc 
receptors by Toxoplasma. The Fc receptor of higher affinity was found to accumulate at 
the polar cap and pre-treatment of the trophozoites with Fc abolished non-specific 
binding of the immunoglobulin (Budzko et al., 1989). False negative reaction of IFA for 
IgM may also occur due to competitive inhibition or blockage by high levels of T. gondii 
specific IgG antibodies (Remington et al., 1985), which may lead to up to 40% of false 
negative results (Van Loon et al., 1983). The IgM fluorescent antibody test has been 
shown to be less sensitive than enzyme linked immunosorbent assays (ELISA) or 
agglutination system (Desmonts et al., 1981).     
 
1.7.3 Complement Fixation Test (CFT) 
The original description of this technique, applied to the measurement of Toxoplasma 
specific antibodies, utilised T. gondii infected hens eggs as an antigen source. 
Subsequently, the sensitivity of the assay was improved with parasites obtained from 
mouse peritoneal inoculation (Fleck and Kwantes, 1980). Antibodies reactive in the 
complement fixation test rise later than those detected in the dye test as the former assay 
measures both membrane and cytoplasm directed immunoglobulin (Welch et al., 1980). 
